IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference

May 15, 2026 8:00 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that it will present new Tau-PET biomarker research at the 2026 Global Tau Conference, taking place May 14-15, 2026, at the Grand Hyatt Washington in Washington, D.C., and online. The poster presentation, titled "Shannon Entropy of Tau-PET Spreading Patterns Predict Alzheimer's...

Read more

Microbix Reports Results for H1 & Q2 2026

May 14, 2026 8:00 AM

Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF)(Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its second quarter and first half of fiscal 2026 ended March 31, 2026 ("Q2" and "H1"). Results for Q2 and H1 demonstrated early results of the Company's continuing work to rebuild revenues back to profitability following two client setbacks in mid-2025, with revenue growth of 5% in H1 compared to H2 fiscal...

Read more

ClearPoint Neuro Reports First Quarter 2026 Results

May 13, 2026 4:05 PM

ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2026.First Quarter 2026 HighlightsReported first quarter revenue of $12.1 million, including $2.3 million of IRRAflow revenue, representing 43% overall growth and 16% year-over-year total organic growth compared...

Read more

ClearPoint Neuro Announces CE Marking of Velocity Alpha MR High Speed Surgical Drill System, Further Expanding Drug Delivery Ecosystem and Global Footprint

May 13, 2026 4:00 PM

ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that the Velocity Alpha® MR High Speed Surgical Drill System has received CE Marking in addition to the existing FDA 510(k) clearance in the United States.The Velocity Alpha MR High Speed Surgical Drill System is manufactured by German-based surgical equipment leader Adeor...

Read more

Cloud-Clone Expands Primary Cell Platform for Global Research Applications

May 13, 2026 12:00 PM

As demand grows for more physiologically relevant research models in drug discovery, cell therapy, and translational medicine, primary cells are becoming increasingly important across life science research workflows. Compared with immortalized cell lines, primary cells more closely retain native biological characteristics, making them valuable tools for disease modeling, toxicity evaluation, biomarker studies, regenerative medicine, and...

Read more

Tex Cycle to Convene 22nd Annual General Meeting

May 13, 2026 10:35 AM

Tex Cycle Technology (M) Berhad ("Tex Cycle" or the "Group"), an established waste management and recycling solutions provider, today held its 22nd Annual General Meeting ("AGM"), where shareholders approved all resolutions tabled.At the AGM, shareholders received the Audited Financial Statements for the financial year ended 31 December 2025, together with the Directors' Report and Auditors' Report. Shareholders also approved the payment of...

Read more

Invitation to FluoGuide A/S Live Webcast on 27 May 2026

May 13, 2026 9:30 AM

FluoGuide A/S (STO:FLUO) will publish its interim report for Q1 2026 on Wednesday, 27 May 2026.Later that day, CEO Morten Albrechtsen and CFO Ole Larsen will present the company's operational and financial results for Q1 2026 in a live webcast. The webcast is hosted and moderated by Cecilia Hallström, BioStock.The presentation will be followed by a live Q&A session, where questions can be asked during the event or submitted in advance by e-mail...

Read more

Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform

May 13, 2026 8:05 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the quarter ended March 31, 2026 and provided a corporate update on the advancement of its innovative DNase oncology platform.Recent HighlightsGenerated robust translational data supporting the DNase I platform...

Read more

Faron to Present New BEXMAB Translational and Clinical Data in HR-MDS at EHA 2026

May 13, 2026 2:20 AM

Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies, today announces that an abstract for its BEXMAB Phase 1/2 study has been accepted as a poster presentation at the European Hematology Association (EHA) 2026 Congress, taking place in Stockholm, Sweden, 11-14 June 2026.The BEXMAB study investigates bexmarilimab in combination with standard...

Read more

AI Maverick Intel Issues 76.5 Million Shares to HEAL Group Holdings Under ROFR Agreement

May 12, 2026 10:00 AM

AI Maverick Intel, Inc. ("AIMV" or the "Company") today announced the issuance of 76,500,000 common shares to HEAL Group Holdings Inc. ("HEAL"), representing an initial tranche of the consideration shares issuable pursuant to the Right of First Refusal Agreement between the parties effective February 11, 2026 (the "ROFR Agreement").As previously disclosed, AIMV has also exercised its right under the ROFR Agreement to acquire 100% of the issued...

Read more

BioInvent's TNFR2 Antibody BI-1808 Shows Strong Activity and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026)

May 12, 2026 10:00 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV)(STO:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that new clinical data from its ongoing Phase 2a trial evaluating BI-1808, its novel anti-TNFR2 monoclonal antibody, in patients with advanced CTCL will be presented at the upcoming European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden. The data underscore BI-1808's...

Read more

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026

May 12, 2026 9:45 AM

BioInvent International (STO:BINV) - BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that it has been selected for a poster presentation of the BI-1206 triplet combination in relapsed/refractory non-Hodgkin's lymphoma (NHL) at the 31st European Hematology Association (EHA2026) Congress, taking place June 11-14, 2026 in Stockholm, Sweden.Poster...

Read more

CEO Statement to Shareholders

May 12, 2026 9:16 AM

As many of our shareholders are aware, OSR Holdings filed its Preliminary Proxy Statement on Schedule PRE 14A with the U.S. Securities and Exchange Commission on May 11, 2026. Given the proximity of our Nasdaq minimum bid compliance deadline, we believe it is important to provide direct and unambiguous transparency regarding our strategy.Notably, the PRE 14A did not include a proposal authorizing a reverse stock split.This was a deliberate...

Read more

enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment

May 12, 2026 9:02 AM

enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), today announced that Robert Berman, Chief Executive Officer of enVVeno Medical participated in a Virtual Investor "What This Means" segment. As part of the segment, Mr. Berman discussed the Company's recent news announcing the U.S. Food and Drug Administration's (FDA) first-ever IDE approval awarded to enVVeno to proceed with a U.S. pivotal study of a non-surgical...

Read more

Repair Biotechnologies Granted Rare Disease Evidence Principles (RDEP) Eligibility by the FDA for REP-0003 in Homozygous Familial Hypercholesterolemia

May 12, 2026 9:00 AM

Repair Biotechnologies, Inc., a biotechnology company developing first-in-class therapies capable of rapidly regressing atherosclerotic plaque, today announced that the U.S. Food and Drug Administration (FDA) has granted eligibility for the Rare Disease Evidence Principles (RDEP) program for its investigational messenger RNA (mRNA) therapy, REP-0003, in the treatment of homozygous familial hypercholesterolemia (HoFH).REP-0003 was granted Orphan...

Read more

MindMaze Therapeutics and Vibra Healthcare Sign Definitive Channel Partnership Agreement to Scale Advanced Neurotherapeutics Across the U.S.

May 12, 2026 1:25 AM

MindMaze Therapeutics, a pioneer in advanced neurotherapeutic technologies, and Vibra Healthcare, a leading provider of neurological care and rehabilitation services, today announced the signing of a definitive channel partnership agreement. The agreement follows the previously announced term sheet and formalizes Vibra's role as a strategic commercial partner to introduce MindMaze Therapeutics' FDA-cleared digital neurotherapeutics platform to...

Read more

First Antibody Derived from AbTherx Platform Advances into Clinical Development

May 11, 2026 9:40 AM

AbTherx, Inc., a privately held biotechnology company focused on accelerating the discovery of next-generation antibody therapeutics, today announced that the first human antibody therapeutic derived from its Atlas™ Mouse platform entered Phase 1 clinical development in Q1 2026.The transition from company inception to clinical validation in under three years highlights the efficiency of the AbTherx discovery engine. This milestone provides the...

Read more

eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program

May 7, 2026 9:05 AM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into nutraceuticals, novel medicines, and valuable chemicals - announced its graduation from the Shell GameChanger™ Accelerator, a multimillion-dollar, multiyear program developed in collaboration between Shell and the U.S. Department of Energy's National Laboratory of the Rockies (NLR).From 2023 to 2026, eXoZymes partnered with...

Read more

enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System

May 7, 2026 8:05 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today reported financial results for the first quarter 2026, ending the quarter with approximately $25 million in cash and investments and confirming the Company's strategic focus on the development of its next-generation enVVe® System for the treatment of deep venous insufficiency. "With a strong balance sheet, significant physician interest in the enVVe valve,...

Read more

Microbix Schedules Release of Results for Q2 Fiscal 2026

May 7, 2026 7:00 AM

Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its second quarter of fiscal 2026 ended March 31, 2026 ("Q2 2026") prior to the start of trading on May 14, 2026. At 10:00 AM ET that day, Microbix intends to hold a webinar discussion of Q2 2026 results with...

Read more